Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,167
  • Shares Outstanding, K 96,914
  • Annual Sales, $ 35,580 K
  • Annual Income, $ -105,320 K
  • EBIT $ -119 M
  • EBITDA $ -123 M
  • 60-Month Beta 2.96
  • Price/Sales 4.47
  • Price/Cash Flow N/A
  • Price/Book 1.15

Options Overview Details

View History
  • Implied Volatility 366.50% (+22.78%)
  • Historical Volatility 68.06%
  • IV Percentile 97%
  • IV Rank 48.26%
  • IV High 688.26% on 04/07/25
  • IV Low 66.34% on 05/21/25
  • Expected Move (DTE 6) 0.2380 (12.59%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 12
  • Volume Avg (30-Day) 175
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 6,771
  • Open Int (30-Day) 6,638
  • Expected Range 1.6520 to 2.1280

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.43
  • Number of Estimates 2
  • High Estimate -0.40
  • Low Estimate -0.45
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +12.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6901 +11.83%
on 02/05/26
2.4700 -23.48%
on 01/14/26
-0.4200 (-18.18%)
since 01/13/26
3-Month
1.6901 +11.83%
on 02/05/26
2.8400 -33.45%
on 12/03/25
-0.5600 (-22.86%)
since 11/13/25
52-Week
1.0900 +73.39%
on 04/17/25
3.6500 -48.22%
on 09/15/25
-1.3100 (-40.94%)
since 02/13/25

Most Recent Stories

More News
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 1.8900 (+3.28%)
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science,...

CCCC : 1.8900 (+3.28%)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 1.8900 (+3.28%)
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

 Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026...

CCCC : 1.8900 (+3.28%)
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 20.03 (+6.71%)
GTBP : 0.4636 (-1.49%)
ROIV : 26.45 (-1.12%)
CCCC : 1.8900 (+3.28%)
BMY : 60.74 (+1.47%)
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 1.8900 (+3.28%)
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds...

CCCC : 1.8900 (+3.28%)
C4 Therapeutics Presents Phase 1 Trial Data

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

CCCC : 1.8900 (+3.28%)
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination...

CCCC : 1.8900 (+3.28%)
Precision Oncology Pipeline Advances from Detection Through Targeted Destruction

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Major biotechnology companies are presenting multi-cancer detection data and breakthrough clinical results...

INTS : 0.2502 (-32.58%)
GRAL : 97.50 (+1.68%)
GTBP : 0.4636 (-1.49%)
PFE : 27.58 (+0.40%)
CCCC : 1.8900 (+3.28%)

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 2.0767
2nd Resistance Point 2.0233
1st Resistance Point 1.9567
Last Price 1.8900
1st Support Level 1.8367
2nd Support Level 1.7833
3rd Support Level 1.7167

See More

52-Week High 3.6500
Fibonacci 61.8% 2.6721
Fibonacci 50% 2.3700
Fibonacci 38.2% 2.0679
Last Price 1.8900
52-Week Low 1.0900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar